

Ensuring accurate classification of *BRCA* variants Run 2

Individual assessment of pathogenicity classification of *BRCA1* and *BRCA2* variants



REGISTRATION IS NOW OPEN!

Description of the G-TACT *BRCA* variant assessment

The aim of this EQA scheme is to provide an online competency assessment for the classification of *BRCA1* and *BRCA2* gene variants related to ovarian cancer and the predicted response to PARP inhibitor treatment. This EQA is open to individuals who classify the pathogenicity of variants and provides assurance of your competency to achieve this accurately and in the most up-to-date manner.



This resource is delivered using the GenQA Genetics Training and Competence Assessment Tool, known as G-TACT. This tool is web-based and can be accessed from any global location, therefore there are no limits to the number of participants.



The Process of Participation

- Individuals will be provided with their own secure password protected website account which gives access to a defined set of *BRCA1* and *BRCA2* gene variants. **If you participated in run 1 (2017) then your account details will be the same.**
- They will be required to review the variants following their routine procedures and submit the classification along with their reasoning to the website.
- Please note: ACMG guidelines will be used for classification in this round of assessments; participants may find it beneficial wish to use these guidelines for their classification.
- Fifteen variants will be provided for EQA run 2.

Benefits of Participation

Following the completion of the EQA run all participants will receive:

- an individual report summarising their classification
- an EQA summary report to enable benchmarking against the expert predicted classifications
- an invitation to access the variant classification videos with explanations and evidence used for the expert predicted classifications
- a certificate of participation

A subsequent teleconference/WebEx will be held to answer any questions and provide educational support.

How to participate in the 2018 scheme

Registration is now open and easy to complete.

- Please complete that online form (<https://www.research.net/r/BRCVariant2018>) to register your interest in participating and we will do the rest.
- All information including key dates and full instructions on how to complete the EQA will be sent to you.
- There is no fee to participate as Astra Zeneca will cover your participation costs. *Please note that Astra Zeneca will not be provided with your identified EQA results.*

Key Dates and Timelines

Activity	Dates
Registration open	3rd April 2018 – 25th May 2018
Assessment active	1st June 2018 – 30th June 2018
- Release of individual results - Access to WebEx videos to review classifications. -1 st call for question submission for Q&A teleconference	August 2018
- Release of Scheme report -2 nd call for question submission for Q&A teleconference	September 2018
Q&A teleconference	September 2018

Additional Information

- This EQA is provided in ENGLISH only.
- The fact that you participate in the scheme and your individual data is confidential between yourself and EMQN/GenQA.
- Further information can be found on the EMQN (www.emqn.org) or the GenQA/UK NEQAS for Molecular Genetics websites (www.genqa.org).
- You can contact the Schemes at office@emqn.org or info@ukneqas-molgen.org.uk